• Further plans for Stevenage campus expansion shared
• Developer partners announced as Reef Group and UBS Asset Management
• GSK to gift land to SBC to enable expansion
STEVENAGE 4th July: Stevenage Bioscience Catalyst (SBC) is based on the life science campus in Stevenage, Hertfordshire. Details of plans to expand the campus were shared today.
The new campus, which will be one of the largest of its kind in the UK and Europe, will be built alongside SBC and its 40+ occupier companies, the Cell and Gene Therapy Catapult and GSK’s existing Global R&D centre. UBS Asset Management and Reef…
05 July 2022
Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
Utilizing Mogrify’s proprietary direct cellular reprogramming platform, the…
Cambridge, UK, 4 July 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled “Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500” has been selected for presentation as part of the Short Oral Discussion Session A at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting, which will be held from 19-23 September 2022 in Stockholm, Sweden and online.
The presentation will take place on Tuesday 20…
Jun 28, 2022
Investment from LifeArc, Illumina, and Illumina Ventures will fund genomics startups for Illumina Accelerator Cambridge graduates
SAN DIEGO, June 28, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health. Illumina Accelerator, located in both San Francisco and…
Cambridge: 24 June 2022
One Nucleus is pleased to announce an exciting collaboration with My Green Lab to support its member organisations in becoming more sustainable. We will be sign-posting the ‘My Green Lab Certification’ complimentary program and providing a discount, exclusive to One Nucleus Members, for the Accredited Professional training courses.
The purpose of this collaboration is to help drive a meaningful and sustainable change within laboratories. Training is currently available for Waste, Procurement and Green Chemistry and, later in the year, Water, Energy and Engagement…
Cambridge’s new urban innovation district welcomes Royal party and guests to celebrate its existing innovative community and mark the next stage of campus development
Cambridge, 28th June 2022: HRH The Duke of Gloucester visited the new Unity Campus development in Cambridge on Friday 24th June.
Welcomed by Nicholas Bewes, CEO, Howard Group, the developer of the site, The Duke and dignitaries, including HM Lord Lieutenant, Mrs Julie Spence OBE and The High Sheriff of Cambridgeshire, Jennifer Crompton began with a tour of The Works building. Completed in February 2020, The…
The development will provide much needed accommodation to the burgeoning life science community within the Cambridge Cluster
Cambridge, UK, 23rd June 2022: Chesterford Research Park has submitted plans to create a new three-storey building on a plot to the east of the Park to meet the high demand for life science space in the Cambridge Cluster.
Subject to planning, the approximately 60,000 sq ft multi-occupier building will be fitted with a mix of laboratory and office space and will be ready for occupation in the summer of 2024.
Named the Sidney Sussex Building…
Andy Billinton PhD appointed as Chief Scientific Officer
Expansion into larger facilities at the Babraham Research Campus
Cambridge, 23rd June 2022: Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.
Transine Therapeutics is developing a novel class of therapeutic RNAs (SINEUPs®) capable of upregulating protein expression with a superior level of control and specificity across an unprecedented range of hard-to-treat diseases, which…
A Charnwood Campus Cluster event, part of a series of events to support the growth and success of the life science organisations clustered around Charnwood Campus Science, Innovation and Technology Park
Business leaders, entrepreneurs, innovators and stakeholders gathered at Charnwood Campus to hear about new ways to encourage innovation and accelerate new product development in collaboration with the NHS and academia, understand how Employee Value Proposition and Corporate Social Responsibility are helping win the war for talent and identify some of the first easy steps on the road map to…
Scorching temperatures, sizzling burgers and great company awaited members of the Norwich Research Park community who joined Anglia Innovation Partnership LLP (AIP) at their community summer barbecue sponsored by Chadwicks and Fortus.
The event was held on the grass and terrace area just outside the Centrum building attended by over 200 guests, from businesses and park partner organisations, who joined in the fun with networking, games and great food from the Genuine Dining Company.
Roz Bird, the new Chief Executive of Anglian Innovation Partnership commented, “Well done to the whole AIP team…